Nassim Usman became the CEO of Catalyst Biosciences, Inc. (NASDAQ:CBIO) in 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider growth that the business demonstrates. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels.
See our latest analysis for Catalyst Biosciences
How Does Nassim Usman's Compensation Compare With Similar Sized Companies?
At the time of writing, our data says that Catalyst Biosciences, Inc. has a market cap of US$82m, and reported total annual CEO compensation of US$1.2m for the year to December 2019. That's actually a decrease on the year before. While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$525k. We examined a group of similar sized companies, with market capitalizations of below US$200m. The median CEO total compensation in that group is US$602k.
Now let's take a look at the pay mix on an industry and company level to gain a better understanding of where Catalyst Biosciences stands. Speaking on an industry level, we can see that nearly 22% of total compensation represents salary, while the remainder of 78% is other remuneration. Catalyst Biosciences is paying a higher share of its remuneration through a salary in comparison to the overall industry.
Thus we can conclude that Nassim Usman receives more in total compensation than the median of a group of companies in the same market, and of similar size to Catalyst Biosciences, Inc.. However, this doesn't necessarily mean the pay is too high. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous. You can see a visual representation of the CEO compensation at Catalyst Biosciences, below.
Is Catalyst Biosciences, Inc. Growing?
Over the last three years Catalyst Biosciences, Inc. has seen earnings per share (EPS) move in a positive direction by an average of 71% per year (using a line of best fit). In the last year, its revenue has collapsed effectively to zero.
This demonstrates that the company has been improving recently. A good result. The lack of revenue growth isn't ideal, but it is the bottom line that counts most in business. Although we don't have analyst forecasts shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.
Has Catalyst Biosciences, Inc. Been A Good Investment?
Given the total loss of 50% over three years, many shareholders in Catalyst Biosciences, Inc. are probably rather dissatisfied, to say the least. So shareholders would probably think the company shouldn't be too generous with CEO compensation.
In Summary...
We compared the total CEO remuneration paid by Catalyst Biosciences, Inc., and compared it to remuneration at a group of similar sized companies. We found that it pays well over the median amount paid in the benchmark group.
Importantly, though, the company has impressed with its earnings per share growth, over three years. Having said that, shareholders may be disappointed with the weak returns over the last three years. One might thus conclude that it would be better if the company waited until growth is reflected in the share price, before increasing CEO compensation. Taking a breather from CEO compensation, we've spotted 6 warning signs for Catalyst Biosciences (of which 2 are potentially serious!) you should know about in order to have a holistic understanding of the stock.
If you want to buy a stock that is better than Catalyst Biosciences, this free list of high return, low debt companies is a great place to look.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
"Ceo" - Google News
March 29, 2020 at 08:02PM
https://ift.tt/2vTFv1U
How Much is Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Getting Paid? - Yahoo Finance
"Ceo" - Google News
https://ift.tt/37G5RC0
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "How Much is Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Getting Paid? - Yahoo Finance"
Post a Comment